Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Current Pharmaceutical Design
Title:Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Volume: 23 Issue: 18
Author(s): Ivana Stojanovic, Mirjana Dimitrijevic, Marta Vives-Pi, Maria Jose Mansilla, Irma Pujol-Autonell, Silvia Rodríguez-Fernandez, Lenka Palova-Jelínkova, David P. Funda, Alisa Gruden-Movsesijan, Ljiljana Sofronic-Milosavljevic, Catharien M. U. Hilkens, Eva Martinez Caceres and Djordje Miljkovic*
Affiliation:
- Institute for Biological Research "Sinisa Stankovic", Department of Immunology, Despota Stefana 142, 11000 Belgrade,Serbia
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Abstract: Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Export Options
About this article
Cite this article as:
Stojanovic Ivana, Dimitrijevic Mirjana, Vives-Pi Marta, Mansilla Jose Maria, Pujol-Autonell Irma, Rodríguez-Fernandez Silvia, Palova-Jelínkova Lenka, Funda P. David, Gruden-Movsesijan Alisa, Sofronic-Milosavljevic Ljiljana, Hilkens M. U. Catharien, Caceres Martinez Eva and Miljkovic Djordje*, Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170214120708
DOI https://dx.doi.org/10.2174/1381612823666170214120708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Synthesis and Applications of Reduced Amide Pseudopeptides
Current Medicinal Chemistry Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Current Pharmaceutical Design Targeting Bacterial Antioxidant Systems for Antibiotics Development
Current Medicinal Chemistry Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Association of Cytokine Gene Polymorphisms (IL6, IL10, TNF-α, TGF-β and IFN-γ) and Graves’ Disease in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-α Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo
Current Neurovascular Research Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Proanthocyanidins in Health Care: Current and New Trends
Current Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Pyrazoles as Promising Scaffold for the Synthesis of Anti-Inflammatory and/or Antimicrobial Agent: A Review
Mini-Reviews in Medicinal Chemistry An Updated Review for the Diabetic Wound Healing Systems
Current Drug Targets Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Rheumatoid Arthritis: Notable Biomarkers Linking to Chronic Systemic Conditions and Cancer
Current Pharmaceutical Design Regulation of Neutrophil Apoptosis and Removal of Apoptotic Cells
Current Drug Targets - Inflammation & Allergy Drug Transfer to the Fetus and to the Breastfeeding Infant: What Do We Know?
Current Drug Delivery